A plasma proteolysis pathway comprising blood coagulation proteases
2 the solution was adjusted to approximately 7.4, using 1 M Tris-HCl (pH 9.5). The mPEPD solution was then concentrated using Ultracel YM-30 Centricon (Millipore). Protein concentration in the sample was measured by the BCA protein assay kit. The mPEPD preparation was checked by western blotting, and its purity was confirmed by SDS-PAGE, followed by silver staining ( Supplementary Fig. 1A and B), using hPEPD for comparison.
Measurement of Potential Activation of FX, FII or FVII by hPEPD
hPEPD (40 nM) was incubated with FX, FII or FVII (0.5 M) in PBS at RT in the presence of 5 mM CaCl 2 for 24 h, followed by IB analysis for potential activation/cleavage of each coagulation factor. FXa, FIIa and FVIIa were used as positive controls in the experiments.
Measurement of Plasma Levels of Aspartate Transaminase (AST) and Alanine

Transaminase (ALT)
Plasma AST activity was measured using the InfinityTM AST (GOT) Reagent kit (Thermo, TR70121). Plasma ALT activity was measured using the InfinityTM ALT (GPT) Reagent kit (Thermo, TR71121). Each assay was performed according to the manufacturer's instruction. a Multiple sets of primers were used to generate this FXII mutant.
